Cognition Therapeutics
CGTX
28 hedge funds and large institutions have $11.4M invested in Cognition Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 6 closing their positions.
148% more capital invested
Capital invested by funds: $4.59M → $11.4M (+$6.81M)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
15.39% more ownership
Funds ownership: 7.56% → 22.96% (+15%)
4% more funds holding
Funds holding: 27 → 28 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$5.71M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.35M |
| 3 |
VC
Voss Capital
Houston,
Texas
|
+$731K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$520K |
| 5 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$317K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$578K |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$310K |
| 3 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$152K |
| 4 |
Two Sigma Investments
New York
|
-$116K |
| 5 |
AC
Apogem Capital
New York
|
-$49K |
CGTX Hedge Fund Activity: Q2 2022 in Review
28 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q2 2022, worth a combined $11.4M — up 148% from $4.59M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CGTX positions and 6 closed out — a net gain of 1 holder — while 10 added to existing stakes and 6 trimmed.
The largest buyer was Pathstone Family Office, opening a new position worth an estimated $5.71M. The largest seller was Kestra Advisory Services, cutting an estimated $578K.
- 28 institutional investors held Cognition Therapeutics (CGTX) as of Q2 2022, up from 27 in Q1 2022.
- Funds reported $11.4M of Cognition Therapeutics stock for Q2 2022, up 148% quarter-over-quarter.
- 7 funds opened new Cognition Therapeutics positions in Q2 2022 and 6 closed out, a net change of +1 holder.
- The largest Cognition Therapeutics buyer in Q2 2022 was Pathstone Family Office, an estimated $5.71M added.
- The largest Cognition Therapeutics seller in Q2 2022 was Kestra Advisory Services, an estimated $578K sold.
Based on aggregated 13F filings for Q2 2022.